Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eicosanoid-producing enzymes represent a broad class of enzymes that catalyze the conversion of polyunsaturated fatty acids, primarily arachidonic acid, into potent lipid signaling molecules known as eicosanoids [1, 2]. This group includes three major enzymatic pathways: the cyclooxygenase (COX) pathway, which produces prostaglandins and thromboxanes; the lipoxygenase (LOX) pathway, which generates leukotrienes and lipoxins; and the cytochrome P450 (CYP) pathway, which produces epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids (HETEs) [1, 3]. These mediators are critical regulators of inflammation, pain, fever, vascular tone, and platelet function [1, 4]. Dysregulation of eicosanoid production is implicated in a wide range of pathologies, including chronic inflammatory diseases like rheumatoid arthritis, respiratory conditions like asthma, cardiovascular diseases, and various cancers [2, 5]. Pharmacological intervention typically involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to inhibit COX enzymes or specific inhibitors like zileuton to target 5-LOX [4, 6]. While highly effective for managing pain and inflammation, targeting these enzymes can lead to significant side effects, such as gastrointestinal bleeding or increased cardiovascular risk, due to the disruption of homeostatic lipid signaling [1, 6]. [1] https://www.ncbi.nlm.nih.gov/books/NBK542314/ [2] https://www.nature.com/articles/nrd.2017.115 [3] https://www.jlr.org/article/S0022-2275(20)30114-1/fulltext [4] https://pubmed.ncbi.nlm.nih.gov/15556670/ [5] https://www.atsjournals.org/doi/full/10.1164/rccm.200204-317PP [6] https://www.nejm.org/doi/full/10.1056/NEJMra052706
Inhibition of specific enzymes within the eicosanoid biosynthetic pathways (e.g., COX-1, COX-2, 5-LOX) to reduce the production of pro-inflammatory or pro-thrombotic lipid mediators [1, 4, 6].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eicosanoid-producing enzymes.